One of the First Staff Members, Fenton Helped Build the World´s
Most Reliable and Efficient Biotechnology Manufacturing Operation
Fabrizio Bonanni, Senior Vice President of Manufacturing, Has Been
Selected to Succeed Fenton
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Aug. 1, 2007--Amgen
(NASDAQ: AMGN) today announced that Dennis Fenton, executive vice
president of Operations, has elected to retire at the end of 2007,
after 25 years with the company. Fenton, 55, is one of Amgen´s
longest-tenured staff members, joining the company during its first 12
months. A research scientist by training, Fenton worked in and led
virtually every part of Amgen over the years including Research,
Process Development, Sales and Marketing, Engineering and
"Dennis will be deeply missed by all of us who have had the
pleasure to work with him over the years. He has been one of the
greatest champions of the Amgen values and a true ambassador of our
heritage," said Amgen Chairman and CEO Kevin Sharer. "As head of
Operations, Dennis helped build the most reliable, efficient and
skilled biotechnology manufacturing operation in the world. For that
achievement, among many others, we are eternally grateful."
Succeeding Fenton as head of Operations, effective immediately,
will be Dr. Fabrizio Bonanni. Since March 2003, Bonanni has been
Amgen´s senior vice president of Manufacturing, overseeing the
company´s site operations and contract manufacturing. Previously, he
was Amgen´s senior vice president, Quality and Compliance, and
corporate compliance officer. Before joining Amgen, Bonanni was
corporate vice president, Regulatory and Clinical Affairs, and
corporate vice president, Quality System for Baxter International Inc.
"One of Dennis´ legacies is the depth and breadth of leadership
within our manufacturing organization. We are pleased to have an
executive of Fabrizio´s experience in a position to effect a smooth
leadership transition in one of Amgen´s most critical areas," said
Succeeding Bonanni as senior vice president, Manufacturing will be
Madhu Balachandran, who was previously vice president, operations at
Amgen Manufacturing, Ltd. in Juncos, Puerto Rico.
Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science´s promise by bringing safe,
effective medicines from lab, to manufacturing plant, to patient.
Amgen therapeutics have changed the practice of medicine, helping
millions of people around the world in the fight against cancer,
kidney disease, rheumatoid arthritis, and other serious illnesses.
With a deep and broad pipeline of potential new medicines, Amgen
remains committed to advancing science to dramatically improve
people´s lives. To learn more about our pioneering science and our
vital medicines, visit www.amgen.com.
CONTACT: Amgen, Thousand Oaks
David Polk, 805-447-4613 (media)
John Shutter, 805-447-1060 (investors)